Clinical Trial Update: A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). [Phase 2]

View source ↗

Summary

Phase 2 study evaluating camrelizumab combined with apatinib in hepatocellular carcinoma patients previously treated with immune checkpoint inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | Status: UNKNOWN